Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 17296, 2017 12 11.
Article in English | MEDLINE | ID: mdl-29229986

ABSTRACT

Insulin resistance plays an important role in obesity-associated asthma exacerbations. Using a murine model of allergic airway inflammation, we evaluated the insulin signaling transmission in lungs of obese compared with lean mice. We further evaluated the effects of the polyphenol resveratrol in the pulmonary insulin signaling. In lean mice, insulin stimulation significantly increased phosphorylations of AKT, insulin receptor substrate 1 (IRS-1) and insulin receptor ß (IRß) in lung tissue and isolated bronchi (p < 0.05), which were impaired in obese group. Instead, obese mice displayed increased tyrosine nitrations of AKT, IRß and IRS-1 (p < 0.05). Two-week therapy of obese mice with resveratrol (100 mg/kg/day) restored insulin-stimulated AKT, IRS-1 and IRß phosphorylations, and simultaneously blunted the tyrosine nitration of these proteins. Additionally, the c-Jun N-terminal kinase (JNK) and inhibitor of NF-κB Kinase (IκK) phosphorylations were significantly increased in obese group, an effect normalized by resveratrol. In separate experiments, the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine (20 mg/kg/day, three weeks) mimicked the protective effects exerted by resveratrol in lungs of obese mice. Lungs of obese mice display nitrosative-associated impairment of insulin signaling, which is reversed by resveratrol. Polyphenols may be putative drugs to attenuate asthma exacerbations in obese individuals.


Subject(s)
Allergens/toxicity , Asthma/prevention & control , Diet, High-Fat/adverse effects , Insulin/metabolism , Obesity/pathology , Pneumonia/prevention & control , Resveratrol/pharmacology , Animals , Asthma/immunology , Asthma/metabolism , Asthma/pathology , Insulin Resistance , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Obesity/etiology , Obesity/metabolism , Phosphorylation , Pneumonia/immunology , Pneumonia/metabolism , Pneumonia/pathology , Receptor, Insulin/metabolism , Signal Transduction
2.
Pulm Pharmacol Ther ; 41: 86-95, 2016 12.
Article in English | MEDLINE | ID: mdl-27816773

ABSTRACT

OBJECTIVES: Activators of soluble guanylyl cyclase (sGC) act preferentially in conditions of enzyme oxidation or haem group removal. This study was designed to investigate the effects of the sGC activator BAY 60-2770 in murine airways inflammation and human eosinophil chemotaxis. METHODS: C57Bl/6 mice treated or not with BAY 60-2770 (1 mg/kg/day, 14 days) were intranasally challenged with ovalbumin (OVA). At 48 h, bronchoalveolar lavage fluid (BALF) was performed, and circulating blood, bone marrow and lungs were obtained. Human eosinophils purified from peripheral blood were used to evaluate the cell chemotaxis. RESULTS: OVA-challenge promoted marked increases in eosinophil number in BAL, lung tissue, circulating blood and bone marrow, all of which were significantly reduced by BAY 60-2770. The IL-4 and IL-5 levels in BALF were significantly reduced by BAY 60-2770. Increased protein expression of iNOS, along with decreases of expression of sGC (α1 and ß1 subunits) and cGMP levels were detected in lung tissue of OVA-challenged mice. BAY 60-2770 fully restored to baseline the iNOS and sGC subunit expressions, and cGMP levels. In human isolated eosinophils, BAY 60-2770 (1-5 µM) had no effects on the cGMP levels and eotaxin-induced chemotaxis; however, prior incubation with ODQ (10 µM) markedly elevated the BAY 60-2770-induced cyclic GMP production, further inhibiting the eosinophil chemotaxis. CONCLUSIONS: BAY 60-2770 reduces airway eosinophilic inflammation and rescue the sGC levels. In human eosinophils under oxidized conditions, BAY 60-2770 elevates the cGMP levels causing cell chemotaxis inhibition. BAY 60-2770 may reveal a novel therapeutic target for asthma treatment.


Subject(s)
Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Eosinophils/drug effects , Hydrocarbons, Fluorinated/pharmacology , Inflammation/drug therapy , Soluble Guanylyl Cyclase/drug effects , Animals , Anti-Asthmatic Agents/pharmacology , Asthma/drug therapy , Asthma/immunology , Bronchoalveolar Lavage Fluid/immunology , Chemotaxis/drug effects , Cyclic GMP/metabolism , Disease Models, Animal , Eosinophils/metabolism , Humans , Inflammation/immunology , Inflammation/pathology , Male , Mice , Mice, Inbred C57BL , Ovalbumin/immunology , Soluble Guanylyl Cyclase/metabolism
3.
Urology ; 86(2): 423.e1-6, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26199165

ABSTRACT

OBJECTIVE: To evaluate the effects of treatment with metformin on a murine model of obesity-associated erectile dysfunction. MATERIAL AND METHODS: C57BL/6 male mice were fed for 10 weeks with standard chow or high-fat diet. Lean and obese mice were treated with the insulin sensitizer metformin (300 mg/kg/day, 2 weeks). Intracavernosal pressure (ICP) and in vitro corpus cavernosum (CC) relaxations to both acetylcholine and electrical field stimulation, as well as phenylephrine-induced contractions, were obtained. Levels of cyclic guanosine monophosphate in CC were detected by enzyme immunoassay. RESULTS: High-fat-fed mice exhibited higher body weight and insulin resistance. Cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly lower in obese compared with lean mice (P <.05). Two-week therapy with metformin reversed the decreased ICP in obese group. The maximal response to acetylcholine in CC was 35% lower (P <.05) in the obese compared to the lean group, which were restored by metformin treatment. Likewise, the impaired electrical field stimulation-induced CC relaxations in obese mice were also partly restored by metformin. Contractile responses to phenylephrine were significantly greater (P <.05) in obese compared to lean mice, which were fully restored by metformin. Basal and stimulated cyclic guanosine monophosphate productions in the erectile tissues were significantly lower (P <.05) in the obese group, an effect fully restored by metformin. CONCLUSION: Treatment with metformin restored the erectile function in obese mice, through improvement of in vitro endothelial and nitrergic cavernosal relaxations. Therefore, use of metformin may be a good pharmacologic approach to treat insulin resistance-associated erectile dysfunction.


Subject(s)
Erectile Dysfunction/drug therapy , Erectile Dysfunction/etiology , Hypoglycemic Agents/therapeutic use , Insulin Resistance , Metformin/therapeutic use , Obesity/complications , Obesity/metabolism , Animals , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL
4.
Cell Rep ; 11(6): 934-943, 2015 May 12.
Article in English | MEDLINE | ID: mdl-25937275

ABSTRACT

Obesity is a major risk factor for asthma, which is characterized by airway hyperreactivity (AHR). In obesity-associated asthma, AHR may be regulated by non-TH2 mechanisms. We hypothesized that airway reactivity is regulated by insulin in the CNS, and that the high levels of insulin associated with obesity contribute to AHR. We found that intracerebroventricular (ICV)-injected insulin increases airway reactivity in wild-type, but not in vesicle acetylcholine transporter knockdown (VAChT KD(HOM-/-)), mice. Either neutralization of central insulin or inhibition of extracellular signal-regulated kinases (ERK) normalized airway reactivity in hyperinsulinemic obese mice. These effects were mediated by insulin in cholinergic nerves located at the dorsal motor nucleus of the vagus (DMV) and nucleus ambiguus (NA), which convey parasympathetic outflow to the lungs. We propose that increased insulin-induced activation of ERK in parasympathetic pre-ganglionic nerves contributes to AHR in obese mice, suggesting a drug-treatable link between obesity and asthma.


Subject(s)
Brain Stem/enzymology , Bronchial Hyperreactivity/complications , Cholinergic Neurons/enzymology , Extracellular Signal-Regulated MAP Kinases/metabolism , Hyperinsulinism/complications , MAP Kinase Signaling System , Animals , Bronchial Hyperreactivity/enzymology , Bronchial Hyperreactivity/physiopathology , Bronchoconstriction , Cholinergic Neurons/pathology , Diet, High-Fat , Enzyme Activation , Hyperinsulinism/enzymology , Hyperinsulinism/physiopathology , Inflammation/pathology , Injections, Intraventricular , Insulin/metabolism , Methacholine Chloride , Mice, Inbred C57BL , Mice, Obese , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Receptor, Insulin/metabolism
5.
J Urol ; 191(2): 539-47, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24050894

ABSTRACT

PURPOSE: Activators of soluble guanylyl cyclase are of potential interest as treatment for cardiovascular diseases but to our knowledge they have never been proposed to treat overactive bladder. We evaluated the effects of the soluble guanylyl cyclase activator BAY 60-2270 on voiding dysfunction and detrusor overactivity in a mouse model of obesity associated overactive bladder. MATERIALS AND METHODS: C57BL/6 male mice fed for 10 weeks with standard chow or a high fat diet were treated with 1 mg/kg BAY 60-2770 per day for 2 weeks via gavage. Cystometric evaluations were done and responses to contractile agents in isolated bladders were determined. RESULTS: Obese mice showed an irregular micturition pattern characterized by significant increases in voiding and nonvoiding contractions, which were normalized by BAY 60-2770. Carbachol, KCl and CaCl2 produced concentration dependent contractions in isolated bladder strips, which were markedly greater in obese than in lean mice. BAY 60-2770 normalized bladder contractions in the obese group. A 78% increase in reactive oxygen species generation in the bladder tissue of obese mice was observed, which was unaffected by BAY 60-2770. Treatment with BAY 60-2770 generated a tenfold increase in cyclic guanosine monophosphate in the bladders of obese mice without affecting the nucleotide level in the lean group. Protein expression of the soluble guanylyl cyclase α1 and ß1 subunits was decreased 40% in the bladder tissue of obese mice but restored by BAY 60-2770. CONCLUSIONS: Two-week BAY 60-2770 therapy increased cyclic guanosine monophosphate and rescued expression of the soluble guanylyl cyclase α1 and ß1 subunits in bladder tissue, resulting in great amelioration of bladder dysfunction.


Subject(s)
Benzoates/therapeutic use , Biphenyl Compounds/therapeutic use , Enzyme Activators/therapeutic use , Guanylate Cyclase/drug effects , Hydrocarbons, Fluorinated/therapeutic use , Obesity/epidemiology , Urinary Bladder, Overactive/drug therapy , Animals , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Blotting, Western , Hydrocarbons, Fluorinated/pharmacology , Lower Urinary Tract Symptoms/drug therapy , Male , Mice , Mice, Inbred C57BL , Reactive Oxygen Species , Urinary Bladder, Overactive/epidemiology , Urinary Bladder, Overactive/prevention & control
6.
PLoS One ; 7(11): e48507, 2012.
Article in English | MEDLINE | ID: mdl-23144896

ABSTRACT

Obesity/metabolic syndrome are common risk factors for overactive bladder. This study aimed to investigate the functional and molecular changes of detrusor smooth muscle (DSM) in high-fat insulin resistant obese mice, focusing on the role of protein kinase C (PKC) and Ca(v)1.2 in causing bladder dysfunction. Male C57BL/6 mice were fed with high-fat diet for 10 weeks. In vitro functional responses and cystometry, as well as PKC and Ca(v)1.2 expression in bladder were evaluated. Obese mice exhibited higher body weight, epididymal fat mass, fasting glucose and insulin resistance. Carbachol (0.001-100 µM), α,ß-methylene ATP (1-10 µM), KCl (1-300 mM), extracellular Ca(2+) (0.01-100 mM) and phorbol-12,13-dibutyrate (PDBu; 0.001-3 µM) all produced greater DSM contractions in obese mice, which were fully reversed by the Ca(v)1.2 blocker amlodipine. Cystometry evidenced augmented frequency, non-void contractions and post-void pressure in obese mice that were also prevented by amlodipine. Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice. The PKC inhibitor GF109203X (1 µM) also reduced the carbachol induced contractions. PKC protein expression was markedly higher in bladder tissues from obese mice, which was normalized by metformin treatment. The Ca(v)1.2 channel protein expression was not modified in any experimental group. Our findings show that Ca(v)1.2 blockade and improvement of insulin sensitization restores the enhanced PKC protein expression in bladder tissues and normalizes the overactive detrusor. It is likely that insulin resistance importantly contributes for the pathophysiology of this urological disorder in obese mice.


Subject(s)
Calcium Channels, L-Type/metabolism , Insulin Resistance , Obesity/complications , Obesity/physiopathology , Protein Kinase C/metabolism , Urinary Bladder, Overactive/complications , Urinary Bladder, Overactive/physiopathology , Adiposity/drug effects , Amlodipine/pharmacology , Animals , Body Weight/drug effects , Calcium Channel Blockers/pharmacology , Calcium Chloride/pharmacology , Carbachol/pharmacology , Disease Models, Animal , Epididymis/drug effects , Epididymis/pathology , Epididymis/physiopathology , In Vitro Techniques , Insulin/pharmacology , Male , Metformin/pharmacology , Mice , Mice, Inbred C57BL , Mice, Obese , Muscle Contraction/drug effects , Obesity/enzymology , Organ Size/drug effects , Phorbol 12,13-Dibutyrate/pharmacology , Potassium Chloride/pharmacology , Thinness/complications , Thinness/physiopathology , Urinary Bladder, Overactive/enzymology
7.
Obesity (Silver Spring) ; 20(10): 1959-65, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22513490

ABSTRACT

Asthma and obesity are growing epidemics in the world. It is well established that obesity worsens the asthma outcomes. High-fat diet-induced obesity in mice exacerbates the pulmonary eosinophilic inflammation. We have used wild-type (WT) and ob/ob mice to further explore the mechanisms by which obesity aggravates the pulmonary eosinophilic inflammation. The eosinophil (EO) number in bronchoalveolar lavage (BAL) fluid, lung tissue, blood, and bone marrow were evaluated at 24, 48, and 72 h after ovalbumin (OVA) challenge in sensitized mice. The basal EO number (phosphate-buffered saline (PBS)-instilled mice) in lung tissue was about 3.5-fold greater in ob/ob compared with WT mice. OVA challenge in ob/ob mice promoted an EO accumulation into the lung that was accompanied by a lower emigration to airways lumen (BAL fluid) in comparison with WT mice. OVA challenge also markedly elevated the number of mature and immature EO in bone marrow of ob/ob mice at 24 h compared with WT group. Blood EO at 48 h was markedly greater in ob/ob mice. Tumor necrosis factor (TNF)-α and interleukin (IL)-10 levels in BAL fluid were significantly higher in ob/ob mice, whereas no changes for IL-5 and eotaxin were found. The IL-6 levels were significantly lower in ob/ob mice. In conclusion, OVA challenge in ob/ob obese mice potentiates eosinophilopoiesis and promotes an accumulation of EO into the lung tissue, delaying their transit to airways lumen. The longer EO remain into the lung tissue is likely to contribute, at least in part, to the asthma worsened by obesity.


Subject(s)
Allergens/immunology , Bone Marrow/immunology , Eosinophils/immunology , Interleukin-6/immunology , Leptin/deficiency , Lung/immunology , Obesity/immunology , Respiratory Hypersensitivity/immunology , Animals , Bone Marrow/pathology , Bronchoalveolar Lavage Fluid/immunology , Cytokines/blood , Disease Models, Animal , Eosinophils/pathology , Female , Inflammation , Leptin/immunology , Leukocyte Count , Lung/pathology , Male , Mice , Mice, Obese , Obesity/complications , Obesity/pathology , Ovalbumin/immunology , Respiratory Hypersensitivity/etiology , Respiratory Hypersensitivity/pathology
8.
Cardiovasc Diabetol ; 11: 5, 2012 Jan 16.
Article in English | MEDLINE | ID: mdl-22248260

ABSTRACT

BACKGROUND: Adiposity greatly increases the risk of atherothrombotic events, a pathological condition where a chronic state of oxidative stress is reported to play a major role. This study aimed to investigate the involvement of (NO)-soluble guanylyl cyclase (sGC) signaling pathway in the platelet dysfunction from high fat-fed (HFF) rats. METHODS: Male Wistar rats were fed for 10 weeks with standard chow (SCD) or high-fat diet (HFD). ADP (10 µM)- and thrombin (100 mU/ml)-induced washed platelet aggregation were evaluated. Measurement of intracellular levels of ROS levels was carried out using flow cytometry. Cyclic GMP levels were evaluated using ELISA kits. RESULTS: High-fat fed rats exhibited significant increases in body weight, epididymal fat, fasting glucose levels and glucose intolerance compared with SCD group. Platelet aggregation induced by ADP (n = 8) and thrombin from HFD rats (n = 8) were significantly greater (P < 0.05) compared with SCD group. Platelet activation with ADP increased by 54% the intraplatelet ROS production in HFD group, as measured by flow cytometry (n = 6). N-acetylcysteine (NAC; 1 mM) and PEG-catalase (1000 U/ml) fully prevented the increased ROS production and platelet hyperaggregability in HFD group. The NO donors sodium nitroprusside (SNP; 10 µM) and SNAP (10 µM), as well as the NO-independent soluble guanylyl cyclase stimulator BAY 41-2272 (10 µM) inhibited the platelet aggregation in HFD group with lower efficacy (P < 0.05) compared with SCD group. The cGMP levels in response to these agents were also markedly lower in HFD group (P < 0.05). The prostacyclin analogue iloprost (1 µM) reduced platelet aggregation in HFD and SCD rats in a similar fashion (n = 4). CONCLUSIONS: Metabolic abnormalities as consequence of HFD cause platelet hyperaggregability involving enhanced intraplatelet ROS production and decreased NO bioavailability that appear to be accompanied by potential defects in the prosthetic haem group of soluble guanylyl cyclase.


Subject(s)
Blood Platelets/metabolism , Diet, High-Fat/adverse effects , Oxidative Stress , Platelet Aggregation , Reactive Oxygen Species/blood , Adenosine Diphosphate , Animals , Antioxidants/pharmacology , Blood Platelets/drug effects , Cyclic GMP/blood , Enzyme Activation , Enzyme Activators/pharmacology , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Glucose Intolerance/blood , Glucose Intolerance/etiology , Glucose Tolerance Test , Guanylate Cyclase/blood , Insulin Resistance , Male , Nitric Oxide/blood , Nitric Oxide Donors/pharmacology , Oxidative Stress/drug effects , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Platelet Function Tests , Rats , Rats, Wistar , Receptors, Cytoplasmic and Nuclear/blood , Signal Transduction , Soluble Guanylyl Cyclase , Thrombin , Time Factors , Weight Gain
9.
BJU Int ; 107(10): 1628-34, 2011 May.
Article in English | MEDLINE | ID: mdl-20942830

ABSTRACT

OBJECTIVE: • Obesity induced by high-fat diet (HFD) is one of the most important risk factor for the development of erectile dysfunction (ED) in man. This study aimed to characterize the ED resulting from obesity associated with HFD in mice. MATERIALS AND METHODS: • C57BL/6 mice fed for 10 weeks with either HFD to induce obesity or a standard-chow diet (SD) were used. Corpus cavernosum was surgically dissected free, and strips were mounted in 10-mL organ baths containing Krebs solution. • Functional responses to endothelium-dependent and -independent agents, as well as to electrical-field stimulation were measured in the cavernosal tissue. Levels of cGMP in erectile tissue were detected by enzyme immunoassay assay. RESULTS: • The potency (pEC(50)) and maximal response (E(max)) to acetylcholine were significantly lower in the HFD group compared with the SD group. A marked decrease in the non-adrenergic non-cholinergic (nitrergic) cavernosal relaxations in the HFD group was also detected. There were no significant differences between the SD and HFD groups for the cavernosal relaxations in response to sodium nitroprusside. • The contractile responses elicited by the α(1) -adrenoceptor agonist phenylephrine were significantly greater in the HFD group compared with the SD group. • Similarly, the electrical-field stimulation (2-8 Hz)-induced adrenergic contractions were markedly greater in HFD mice. The pEC(50) for endothelin-1 was about 6.9-fold higher in the HFD compared with SD group. • The basal cGMP content was 47% lower in HFD strips compared with SD group. There were no morphological alterations in erectile tissue of HFD group compared with SD mice. CONCLUSION: • Obesity associated with HFD favours ED as result of impaired endothelial and nitrergic cavernosal relaxations along with increased contractile responses to adrenergic stimulation and endothelin-1 receptor activation.


Subject(s)
Dietary Fats/adverse effects , Impotence, Vasculogenic/etiology , Nitric Oxide/metabolism , Obesity/complications , Penile Erection/physiology , Penis/physiopathology , Animals , Cyclic GMP , Impotence, Vasculogenic/physiopathology , Male , Mice , Mice, Inbred C57BL , Obesity/etiology , Obesity/physiopathology , Receptor, Endothelin A/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...